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Maintenance of immunological tolerance is a critical hallmark of the immune system. Sev-
eral signaling checkpoints necessary to balance activating and inhibitory input to immune
cells have been described so far, among which the E3 ligase Cbl-b appears to be a central
player. Cbl-b is expressed in all leukocyte subsets and regulates several signaling pathways
in T cells, NK cells, B cells, and different types of myeloid cells. In most cases, Cbl-b neg-
atively regulates activation signals through antigen or pattern recognition receptors and
co-stimulatory molecules. In line with this function, cblb-deficient immune cells display
lower activation thresholds and cblb knockout mice spontaneously develop autoimmunity
and are highly susceptible to experimental autoimmunity. Interestingly, genetic associ-
ation studies link CBLB-polymorphisms with autoimmunity also in humans. Vice versa,
the increased activation potential of cblb-deficient cells renders them more potent to
fight against malignancies or infections. Accordingly, several reports have shown that cblb
knockout mice reject tumors, which mainly depends on cytotoxic T and NK cells. Thus, tar-
geting Cbl-b may be an interesting strategy to enhance anti-cancer immunity. In this review,
we summarize the findings on the molecular function of Cbl-b in different cell types and
illustrate the potential of Cbl-b as target for immunomodulatory therapies.
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MODULATION OF IMMUNE CELL FUNCTIONS BY THE E3
LIGASE Cbl-b
Ubiquitination represents an important post-transcriptional reg-
ulatory mechanism of various cellular pathways. The specificity of
this process is conferred by E3 ubiquitin ligases. Over the last
decade, many E3 ubiquitin ligases involved in the fine-tuning
of immunological responses have been described (1–3). Among
these, Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b)
stands out as one of the most important gate keepers of immune
activation due to its function as a non-redundant negative regu-
lator of immune activation (4–7). Here, we report on the recent
advances in our understanding of the molecular function of Cbl-b
and discuss potential clinical implications of Cbl-b targeting for
cancer immunotherapy.
Abbreviations: ACT, adoptive cell transfer; AP-1, activator protein-1; APC, anti-
gen presenting cell; BCR, B cell receptor; BLNK, B cell linker protein (=SLP-65,
BASH); BMDC, bone marrow derived dendritic cell; BTK, Bruton’s tyrosine kinase;
Cbl-b, Casitas B-lineage lymphoma proto-oncogene B; C/EBP-b, CCAAT-enhancer
binding protein beta; CIN85, Cbl-interacting protein of 85 kDa; CTLA-4, cytotoxic
T-lymphocyte antigen 4; DC, dendritic cell; DEC-205, CD205; EAE, experimental
autoimmune encephalomyelitis; FOX, forkhead box; Fyn, proto-oncogene; ICAM-
1, intercellular adhesion molecule 1; IFN-γ, interferon gamma; IKK α/β, inhibitor
of NF-κB kinase alpha/beta; IL-2, interleukin-2; KIR, killer-Ig-like receptor; LAT,
linker for activation of T cells; Lck, lymphocyte specific tyrosine kinase; LCMV,
lymphocytic choriomeningitis virus; LFA-1, leukocyte function-associated antigen
1; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; MICA, MHC I
polypeptide related sequence A; MIP-1, macrophage inflammatory protein-1; MCP-
1, monocyte chemoattractant protein-1; mTOR, mammalian target of rapamycin;
MyD88, myeloid differentiation primary response gene; Nedd4, neural precursor
cell expressed developmentally down-regulated protein 4; NFAT, nuclear factor of
PROTEIN UBIQUITINATION
Post-transcriptional protein modification such as ubiquitination
adds an additional important layer to the regulation of cellular
processes. Ubiquitin (Ub) is a 76 amino acid peptide, which is
tagged to proteins through a process involving three enzymes: E1,
E2, and E3. Ubiquitination is initiated by an ubiquitin activat-
ing enzyme (E1) forming a thiol ester bond with the C-terminal
glycine residue of ubiquitin. The activated Ub can then be trans-
ferred to one of the Ub conjugating enzymes (E2) via a similar
thioester linkage. In a final step, E3 ligases catalyze the formation
of an isopeptide bond between Ub and a specific lysine residue
of the target protein (8, 9). In addition to 2 E1 and 35 E2 ligases,
the mammalian genome encodes over 1000 E3 proteins, which
activated T cells; NF-κB, nuclear factor of κB; NKG2D, killer cell lectin-like receptor;
OVA, ovalbumin; PAMP, pathogen-associated molecular patterns; PD1, programed
cell death 1; PD-L1, programed cell death ligand 1; PKCθ, protein kinase C-theta;
PI3K, phosphatidylinositol 3-kinase; PLCγ, phospholipase C-gamma; PTEN, phos-
phatase and tensin homolog; PTK, phospho tyrosine kinase; Rac, member of Rho
family GTPases; rag2, recombination activating gene-2; RANK, receptor activator of
NF-κB; RANTES, regulated on activation, normal T cell expressed and secreted; Ras,
member of family of small GTPases; RING, really interesting new gene; SH2, Src
homology domain; SIINFEKL, OVA257–264 peptide; SLP76, SH2 domain containing
leukocyte protein of 76kD; SMAD7, mothers against decapentaplegic homolog 7;
Src, proto-oncogene Src; TAM, tyro3, axel, mer family of TAM receptor tyrosine
kinases; TCR, T cell receptor; TNF-α, tumor necrosis factor-alpha; TKB, tyrosine
kinase binding domain; TRAF, TNF receptor-associated factor; TRIF, TIR-domain
containing adapter; TGF-β, transforming growth factor-beta; TLR, toll-like recep-
tor; Treg, regulatory T cell; TRK, receptor tyrosine kinase; Ub, ubiquitin; UBA,
ubiquitin-associated domain; Vav1, protooncogene Vav1; VLA-4, very late antigen
4; WASP, Wiskott–Aldrich syndrome protein; Wt, wildtype; ZAP-70, zeta-associated
protein of 70 kDa.
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are responsible for the broad range of target proteins regulated by
ubiquitin modification (10).
Poly ubiquitination via lysine residue K48 serves as a
proteasome-targeting signal leading to degradation of the sub-
strate protein via the 26S proteasome while mono-ubiquitination
or poly ubiquitination via other lysine residues, e.g., K63, mainly
modifies protein function by altered protein trafficking and
subcellular localization (11, 12). Cytoplasmic signaling proteins
and nuclear transcription factors tend to be ubiquitinated for
proteasomal degradation while surface receptors like receptor
tyrosine kinases, G-protein-coupled receptors, and the TCR are
more often regulated by endocytosis and subsequent lysosomal
degradation (13–15).
MOLECULAR MECHANISMS OF Cbl-FAMILY E3 LIGASES
The Cbl proteins are encoded by a highly conserved gene fam-
ily, which can be found from nematodes to mammals (16). The
name is derived from the retroviral oncoprotein v-Cbl promoting
development of B cell leukemia in mice. V-Cbl represents a dom-
inant mutant antagonizing the function of its cellular homolog
c-Cbl (17, 18). The mammalian genome encodes three Cbl pro-
teins (Figure 1): c-Cbl (also termed Cbl2, Cbl-SL, or RNF55) (18),
Cbl-b (also termed RNF56) (19), and Cbl-c (also called Cbl-3) (20,
21). While c-Cbl and Cbl-b are expressed in a wide range of tissues,
expression of Cbl-3 and another structurally similar E3 ligase, Cbl-
like protein-1 (CBLL1, also called HAKAI) is restricted to epithelia
(17, 19–23). Recently, ZNF645, a new E3 ligase with structural
homologies to Cbl proteins, has been described as testis specific
gene (24). Cbl proteins interact with target proteins via their
protein–protein interaction domains (Figure 1), allowing regula-
tion of multiple pathways (25). This interaction involves recogni-
tion of specific phosphotyrosine-containing sequence motifs that
are generated on protein tyrosine kinases (PTK). Thus, the current
paradigm holds that Cbl-family E3 ligases are selective regulators
of activated PTKs (26).
All three mammalian Cbl proteins are RING-type E3 ligases
containing an N-terminal tyrosine kinase binding (TKB) domain
consisting of a four-helical bundle, a calcium binding EF-hand
and a Src homology (SH2) domain, followed by a linker helical
region and the RING domain (Figure 1), responsible for their
catalytic function (16, 27–32). The evolutionary highly conserved
N-terminal RING-type zinc finger domains forming the basic E3
module of Cbl proteins are essential and sufficient for activated
PTK directed E3 ligase activity (33, 34) as evidenced by a loss of
function mutation in the E3 ligase domain of cblb, which phe-
nocopies the cblb knockout phenotype in vivo (35). Additionally,
c-Cbl and Cbl-b contain proline-rich regions mediating the asso-
ciation with tyrosine- and serine phosphorylation sites, and an
ubiquitin-associated (UBA)/leucine zipper domain for dimeriza-
tion (Figure 1) (16, 36–38). Via their protein interaction domains
Cbl proteins interact with a large number of target proteins either
as E3 ligases or adaptor molecules, e.g., with Src family kinases,
SH2-domain containing proteins of the PTK-dependent signaling
network including Vav guanine exchange factors, the p85 subunit
of phosphatidylinositol 3-kinase (PI3K), and adaptor proteins of
the Crk-family allowing the regulation of multiple pathways (26).
Proteins ubiquitinated by Cbl proteins are either degraded in the
proteasome or sequestered to specific cellular locations. Of the
three Cbl proteins in mammals, Cbl-b is preferentially expressed
in peripheral lymphoid organs suggesting a prominent function
for adaptive immune responses. Specifically, Cbl-b seems to be
central for maintenance of peripheral tolerance as cblb knock out
mice develop spontaneous autoimmunity characterized by auto-
antibody production and infiltration of activated T and B cells
into multiple organs (4, 5). Cbl-linked networks (Figure 2) have
been implicated in the control of the immune system, cell prolif-
eration, differentiation, and cell morphology (25, 39). Spatial or
temporal dysregulation of Cbl proteins results in autoimmunity
or increased tumor progression.
Cbl-b FUNCTION IN T CELLS
Cbl-b is highly expressed in murine and human CD4+ and CD8+
T cells (GFN SymAtlas, http://biogps.org) and its expression levels
are tightly regulated by CD28 and CTLA-4 stimulation (40, 41) and
FIGURE 1 | Functional domains of human Cbl and Cbl-like proteins.
Three N-terminal regions [4-helical bundle (4H), EF-hand domain, and SH2
domain] constitute the tyrosine kinase binding (TKB) domain. Separated by a
conserved linker (L) region follows a RING finger (RF) domain, which binds
to E2 enzymes. The proline-rich sequence (PR) interacts with SH3 domains
of various proteins involved in signaling and endocytosis. In the Cbl-like
proteins, the order of the RF and TKB (here comprising a single C3H2
domain) is reversed. Only c-Cbl and Cbl-b contain an ubiquitin-associated
domain (UBA) involved in binding and dimerization of ubiquitin. Several
tyrosine residues in the L region and in the less conserved C-terminal half
can be phosphorylated, resulting in conformational changes necessary for
the ligase activity or interaction with SH2 domains of signaling proteins.
Mutations associated with myeloproliferative disorders are located in the RF
and L regions.
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FIGURE 2 | Interaction of Cbl-b with signaling pathways in diverse
cells. Black receptors represent activating signaling pathways, red
receptors inhibitory pathways. Black arrows indicate positive regulation,
red bar-headed lines are representative for negative regulation. Dotted
lines indicate secretion of proteins. Regulation of Cbl-b occurs not only at
the transcriptional level but also by post-transcriptional mechanisms such
as phosphorylation, degradation, or sequestration to specific protein
complexes.
other co-stimulatory and inhibitory signals (Figure 2) (42). Over
the years, work by several groups has documented an essential role
of Cbl-b in the negative regulation of T cell activation (6, 7, 39).
T cell activation and tolerance induction are tightly controlled
processes regulating immune responses to pathogens and tumors
while preventing autoimmunity. Autoimmunity is mainly averted
through central tolerance by negative selection of thymocytes car-
rying TCR for self-antigens (43, 44). However, mechanisms of
peripheral tolerance are needed for T cells that escaped thymic
selection, and include tolerance of low level expressed or low-
affinity antigens, immunosuppression mediated by regulatory T
cells (Treg), and other suppressive cell populations, induction
of anergy, e.g., in the absence of co-stimulation and activation-
induced cell death (43, 45, 46). While maintaining tolerance
prevents autoimmunity on one hand, tumor induced anergy
induction of T cells is critical and hazardous on the other hand.
Immunosuppression by cancer cells involves induction and expan-
sion of various immunosuppressive cell types such as Tregs and
myeloid derived suppressor cells as well as production of inhibit-
ing cytokines, e.g., transforming growth factor-beta (TGF-β), and
finally supports tumor cells to escape the immune system (47).
T cells require two signals for proper activation: the first pro-
vided by interaction of the TCR complex with the cognate peptide
antigen presented by major histocompatibility complex molecules
and a second through co-stimulatory molecules on antigen pre-
senting cells. Following initial triggering of the antigen receptor,
the Src family kinases Lck and Fyn are recruited to phospho-
rylate ZAP-70, which subsequently phosphorylates SLP-76 and
LAT. Subsequently, a multi-subunit protein complex containing
inducible T cell kinase, PI3K, phospholipase C-γ (PLCγ), and Vav1
is formed resulting in PLCγ-regulated calcium influx, cytoskele-
tal rearrangements via Vav1, Rac, WASP, and activation of pro-
tein kinase C-theta (PKCθ) (48). PKCθ is a key molecule of the
immunological synapse responsible for cytokine responses, pro-
liferation of T cells (49), and TH17-mediated autoimmunity (50).
The sustained calcium influx following TCR engagement activates
the phosphatase calcineurin, which subsequently dephosphory-
lates the NFAT family of transcription factors. Dephosphorylated
NFAT proteins then translocate to the nucleus to induce expression
of various genes (51).
Final activation of T cells is achieved by a second signal deliv-
ered by several co-stimulatory molecules, of which CD28 is the
most prominent. CD28 is activated by binding to its ligands CD80
or CD86 to enhance TCR proximal signaling and to induce addi-
tional pathways, leading to activation of NF-κB, NFAT, and AP-1
transcription factors (52). Cooperation of NFAT with AP-1 is
required for IL-2 gene transcription and mRNA stability (51).
Furthermore, CD28 co-stimulation leads to cytoskeletal reshuffle

























































Lutz-Nicoladoni et al. Immune regulation by Cbl-b
in order to form and stabilize the immunological synapse. Strong
TCR stimulation without co-stimulation or TCR stimulation by a
low-affinity antigen results in T cell anergy instead of activation
(53) and anergic T cells remain in a viable, but unresponsive state.
After receiving tolerizing signals, e.g., TCR stimulation in the
absence of co-stimulation, Cbl-b is up-regulated (40, 41) and
inhibits signaling events downstream of PI3K. In Jurkat cells, this
was mediated by ubiquitination of the p85 subunit of PI3K leading
to reduced interaction of p85 with CD28 (54). However, ubiquiti-
nation of p85 was never shown in primary cells, and these findings
have recently been challenged by a report that Cbl-b does not
directly inhibit PI3K, but suppresses PTEN inactivation indepen-
dently of its ubiquitin ligase activity (55). Cbl-b associates with
Nedd4 inhibiting its autophosphorylation and subsequent ubiq-
uitination of PTEN, thereby inhibiting down-regulation of PTEN.
In addition, introducing nedd4 deficiency into cblb-deficient mice
abrogates the hyperresponsive phenotype of cblb−/− T cells. As
these experiments have been exclusively performed in murine
models, it is still possible that direct effects of Cbl-b on PI3K
contribute to the modulation of CD28 signaling in human T cells.
Furthermore, Cbl-b reduces phosphorylation and activation of
PLCγ-1 in anergic cells. Accordingly, loss of Cbl-b rescues reduced
calcium mobilization of anergic T cells, resulting in impaired
induction of T cell tolerance (56). Cbl-b regulates calcium influx
and IL-2 production through Vav-1 activation (57). Cbl-b directly
interacts with Vav1 through its N-terminal proline-rich region,
thereby controlling phosphorylation of Vav1, but not by targeting
it for degradation. Whereas in wild-type cells TCR plus CD28 core-
ceptor stimulation is required for Vav1 activation, in cblb-deficient
cells sole TCR stimulation is sufficient for Vav1 activation (57),
which is important for formation and stability of the immuno-
logic synapse. Cbl-b and c-Cbl together promote antigen-induced
down-regulation of the TCR (58). Moreover, Cbl-b was shown
to repress NF-κB transactivation (59). Following stimulation of
CD28, Cbl-b is post-transcriptionally eliminated by ubiquitina-
tion and proteasomal degradation, which is a prerequisite for the
maintenance of T cell proliferation and IL-2 production (41).
Gruber et al. described an antagonistic cross-talk between PKCθ
and Cbl-b, which colocalize upon TCR and CD28 co-stimulation,
resulting in phosphorylation of Cbl-b by PKCθ probably induc-
ing a conformational change of Cbl-b (60). Subsequently, Cbl-b
is ubiquitinated by the E3 ligase Nedd4 mediating proteasomal
degradation (61). In summary, genetic loss of Cbl-b in naive T
cells uncouples TCR stimulation from the requirement of CD28
co-stimulation for effective proliferation and IL-2 secretion. Cblb-
deficient T cells are hyperresponsive, and even upon TCR stim-
ulation in the absence of CD28 co-stimulation they proliferate
comparable to wild-type T cells after double stimulation with
anti-CD3 and anti-CD28 antibodies (4, 5).
Cbl-b is also involved in activation-induced cell death. Cblb-
deficient CD4+ TH1 cells are resistant to apoptosis induction by
CD3 stimulation in the absence of CD28+ co-stimulation (62)
and also clonal deletion of CD8+ T cells was shown to depend on
Cbl-b (63, 64). This is important in the context of chronic viral
infection where virus-specific CD8+ T cells become exhausted. It
was shown that functional impairment (exhaustion) and to a lesser
extent also elimination of virus-specific T cell clones was delayed in
Cbl-b deficient animals persistently infected with LCMV leading
to immunopathology and decreased survival (63).
The central role of Cbl-b in the maintenance of the bal-
ance between T cell tolerance and T cell activation is mirrored
in the autoimmune phenotype of cblb knock out mice. Despite
normal T cell development cblb knock out mice are highly sus-
ceptible to experimental autoimmune encephalomyelitis (5). Fur-
thermore, depending on the genetic background cblb-deficient
mice develop spontaneous autoimmunity characterized by auto-
antibody production, infiltration of activated T and B lymphocytes
into multiple organs, increased size of submandibular gland, and
parenchymal damage starting at 6 months of age (4). Along this
line, increased collagen-induced autoimmune arthritis induced by
immunization and subsequent boosting with collagen is found in
cblb knock out DBA/1 mice compared to wildtype (wt) DBA/1
mice (56). In another model of anergy induction in T cells
p14/TCRVaVb8.2 transgenic mice recognizing the LCMV p33 pep-
tide presented by MHC class I were injected with the cognate
p33 peptide. On a cblb-deficient background increased in vivo
expansion of antigen-specific T cells was detected, and instead of
anergy the rechallenge with p33 induced a cytokine storm followed
by massive edemas in multiple organs and high mortality of the
animals (56).
Cbl-b controls the threshold for T cell activation (40, 41) and
regulates the affinity of antigens to their TCR (65). Gronski et al.
demonstrated increased development of autoimmune diabetes by
crossing p14/Rip-gp transgenic mice onto a cblb−/− background.
About 100% of cblb-deficient p14/Rip-gp mice versus <50%
of cblb+/+ p14/Rip-gp mice developed diabetes when infected
with LCMV expressing the low-affinity ligand LF6, accompa-
nied by enhanced T cell proliferation and enhanced cytotoxic
T-lymphocyte function in cblb-deficient mice (65).
Transforming growth factor-β plays a central role in T cell dif-
ferentiation (66) by inhibiting TH1 and TH2 polarization (67)
and triggering differentiation of inducible Tregs or, in coopera-
tion with IL-6, induction of TH17 cells (68). Additionally, TGF-β
exerts immune suppressive functions and inhibits T cell activ-
ity averting development of autoimmunity (69). TGF-β secretion
by tumor cells and tumor-infiltrating Tregs therefore contributes
to immune evasion of tumor cells (70). Cbl-b deficiency ren-
ders peripheral CD4+ and CD8+ T cells partially resistant to
inhibitory effects exerted by Tregs via disruption of the TGF-β
pathway (56, 71–76). The interaction of CD4+CD25+ regula-
tory T cells and CD4+CD25− effector cells in cblb−/− mice was
extensively studied by Wohlfert et al. (75), demonstrating normal
function of cblb-deficient Tregs, but resistance of cbl-b deficient
CD4+CD25− T cells to inhibition by either Tregs or soluble TGF-
β. In the presence of TGF-β, naive CD4+CD25+ T cells can be
converted into CD4+CD25+FoxP3+ inducible Tregs (77). This
differentiation is negatively regulated by the PI3K/Akt/mTOR and
the FOXO1/3a pathway (78, 79). Cbl-b promotes TGF-β-mediated
iTreg conversion by tuning the threshold of T cell activation via
an Akt2-dependent mechanism (80). Recently, SMAD7, a negative
regulator of TGF-β receptor signaling, was identified as a criti-
cal target of Cbl-b (81), thus regulating sensitivity toward TGF-β
effects. On a molecular level, Cbl-b directly interacts with and
ubiquitinates SMAD7, targeting it for degradation and thereby
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increasing TGF-β/SMAD signaling in T cells. Accordingly, resis-
tance of cblb-deficient T cells to TGF-β is abrogated by conditional
deletion of SMAD7 (81).
Moreover, Cbl-b seems to be involved in the negative regula-
tion of CD8+ T cells via the interaction of programed cell death
ligand 1 (PD-L1) on dendritic cells (DCs) programed cell death 1
(PD1). It was recently shown that PD-L1 silencing in DC blocks
up-regulation of Cbl-b in CD8+ T cells after antigen presenta-
tion resulting in hyperactive pro-inflammatory TCRhigh CD8+ T
cells and accelerated anti-tumor immune responses in the EG.7
mouse tumor model (42). Regulation of Cbl-b by PD1 possibly
contributes to the clinical benefit seen in patients with advanced
cancer after treatment with antibodies blocking the interaction
between PD1 and PD-L1 (82, 83). Similarly, the improved sur-
vival after treatment of melanoma patients with CTLA-4 blocking
antibodies (84) may also involve Cbl-b down-regulation as activa-
tion of CTLA-4 increases Cbl-b levels by transcriptional regulation
(Figure 2) (40).
Recent evidence suggests that Cbl-b is also involved in the
polarization of T helper cells into functionally distinct subsets.
Levels of Cbl-b are significantly lower in TH2 and TH9 cells
compared to TH1 and TH17 cells, and in vitro differentiation of
naïve T cells from cblb knock out mice yielded more TH2 and
TH9 cells in comparison to those derived from wt mice (85).
In addition, absence of Cbl-b resulted in stronger TH2 and TH9
responses and was associated with severe airway inflammation
in a mouse model of asthma (85). This, however, is somewhat
in contrast to a previous report where, using a different mouse
strain and different immunization protocols, increased suscepti-
bility to asthma induction in cblb-deficient mice was mediated
by a TH1 response in the lung (86). IL-4 signaling through the
JAKs/Stat6 pathway is essential for both TH2 and TH9 differenti-
ation (87). Cbl-b was shown to bind to Stat6 via its TKB domain
leading to ubiquitination and degradation though the protea-
some, explaining increased signaling through the Stat6 pathway
in cblb−/− cells, and finally increased TH2 differentiation (85).
The molecular mechanism of increased TH9 differentiation, how-
ever, remains completely unclear, especially because TH9 cells
require an active TGF-β signal to be differentiated, which, how-
ever, is blocked due to the accumulation of the inhibitory SMAD7,
mentioned above.
TARGETING Cbl-b IN T CELLS FOR TUMOR IMMUNOTHERAPY
As already shown for various other checkpoint regulators, genetic
loss of the Cbl-b protein leads to autoimmunity but is linked to
improved tumor immune surveillance. A recent report using a
shRNA screen for major immune regulators governing anti-cancer
immune responses supports the importance of Cbl-b as check-
point molecule (88). Along this line cblb-deficient animals reject
tumors in various autochthonous and transplanted tumor models
(4, 5). Moreover, mice carrying a cblb E3 ligase-defective mutation
are resistant to tumor formation in vivo and reject experimental
and spontaneous malignancies (35, 72, 73). As demonstrated by
several groups, including our own, this effect is mainly mediated
by CD8+ cytotoxic T cells and NK cells (73, 89).
In more detail, TC-1 cells, c-H-ras-transformed syngenic
fibroblasts expressing the human papilloma virus 16-derived
oncoproteins E6 and E7 were subcutaneously injected into wild-
type, heterozygous, and cblb knockout C57BL/6 mice (73). Tumor
growth and histology of tumors were unaltered between the groups
during the first 2 weeks after tumor cell inoculation, however, after
2 weeks cblb-deficient recipients started to reject tumors spon-
taneously and tumor masses were continuously reduced until
tumors even became undetectable in some animals. This strong
anti-tumor response was paralleled by an increased tumor infil-
tration rate of CD8+ T cells while numbers of tumor-infiltrating
CD4+ T cells were unaltered. Moreover, increased numbers of
INF-γ secreting CD8+ T cells could be detected in the draining
lymph nodes. Treg cells infiltrated TC-1 tumors in both cblb+/+
and cblb−/−mice; however, loss of Cbl-b dramatically changed the
ratio of CD8+ T cells to Tregs, which is also a strong predictor of
improved outcome in human cancer (90). These findings are sup-
ported by the work of Chiang et al. (72), who demonstrated that
cblb-deficient mice efficiently rejected subcutaneously inoculated
EL4 and EG7 lymphoma cells lacking B7 co-stimulatory mole-
cules. EL4 T linage lymphoma cells represent a tumor model with
weak immunogenicity as well as reported TGF-β secretion, while
EG7 cells are highly immunogenic EL4 transfectants expressing
chicken ovalbumin (OVA) as model tumor antigen. Tumor growth
of both cell lines was dramatically reduced in cblb-deficient ani-
mals demonstrating that genetic ablation of Cbl-b provokes the
ability to reject or attenuate growths of weak and highly immuno-
genic tumors independent of CD28-co-stimulation of effector
cells. Furthermore, when crossing ataxia telangiectasia mutated
(ATM) deficient mice onto a cblb-deficient background, 50% of
ATM−/− cblb+/+ mice died within 6 months of age of sponta-
neous T cell lymphomas while no death was observed among
ATM−/− cblb−/− double knockout mice. Further studies using
Cbl-b E3 ligase-defective (C373Aki/Ki) knock in mice (91) revealed
that selective genetic inactivation of Cbl-b ligase activity pheno-
copies the total loss of Cbl-b, resulting in hyperactivation of T cells,
impaired induction of T cell anergy, spontaneous autoimmunity,
and tumor rejection demonstrating that the catalytic function of
Cbl-b is essential for negative regulation of T cells in vivo (35).
The observed increased anti-tumor response seems to be in
part the result of TGF-β insensitivity due to SMAD7 degra-
dation after Cbl-b ubiquitination. To evaluate the in vivo rel-
evance of Cbl-b in SMAD7 regulation, cblb knockout mice
were crossed with CD4Cre-smad7fl/fl knockout mice to gener-
ate T cell-specific cblb/smad7 double knockout animals, which
were investigated concerning their in vivo anti-tumor responses
(81). While subcutaneously injected TC-1 tumors are efficiently
rejected in cblb single knockout mice, they substantially grow
in T cell specific double knockout mice that display compara-
ble survival rates to wildtype animals indicating that concomitant
loss of smad7 abrogates the survival benefit of cblb-deficient
mice. This insensitivity of cblb-deficient T cells to negative cues
from the tumor microenvironment contributes to their increased
anti-tumor efficacy.
The above studies also investigated a possible therapeutic effi-
cacy of adoptively transferred cblb-deficient T cells in tumor-
bearing hosts. Immunodeficient recombination activating gene-2
(rag2)−/− mice, lacking both T and B cells, were inoculated with
TC1 tumor cells and treated with adoptive cell transfer (ACT) of
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CD8+ T cells from either wt or cblb-deficient donor mice. In con-
trast to adoptively transferred wt cells, cblb-deficient naive CD8+ T
cells were able to markedly delay tumor growth (73). Nevertheless,
ACT of polyclonal cblb-deficient CD8+ T cells into immunocom-
petent wild-type mice yielded contradictory results. While Chiang
et al. showed that ACT of cblb-deficient CD8+ T cells into EG.7
tumor-bearing C57Bl/6 wt mice led to delayed tumor outgrowth
or even eradication of established tumors (72), we found that sole
ACT of polyclonal cblb-deficient CD8+ T cells in immunocom-
petent wildtype mice challenged with either EG.7 lymphoma or
B16.ova melanoma, was not sufficient to significantly delay tumor
growth (74). In contrast to other reports (92–95), we did not trans-
fer TCR transgenic tumor-antigen specific but polyclonal T cells.
Moreover, we used immunocompetent wildtype recipient mice
and did not combine the ACT with induction of lymphopenia as
often approached (92). As monotherapy with cblb-deficient poly-
clonal CD8+ T cells did not provoke any benefit in neither B16.ova
melanoma nor EG.7 lymphoma injected immunocompetent mice
in our hands, we established a combination therapy of ACT of cblb-
deficient CD8+ T cells and DC vaccination, resulting in delayed
tumor outgrowth and significantly prolonged survival rates when
DC vaccination was combined with ACT of cblb-deficient instead
of wt CD8+ T cells (74). The enhanced anti-tumor activity was
accompanied by a significantly higher CD8+ T cell infiltration into
the tumor and significantly increased numbers of tumor-antigen-
positive OVA-specific CD8+ T cells as well as IFN-γ secreting cells
in the tumor draining lymph node. Furthermore, specific killing of
peptide-loaded target cells was significantly increased in B16.ova
bearing mice treated with antigen-pulsed wt DCs and ACT of
cblb−/− CD8+ T cells compared to animals challenged with the
DC vaccine in combination with wt CD8+ T cells. Vaccination
with tumor antigen-pulsed DCs thereby provide a second stimulus
leading to an efficient accumulation and in vivo selection of tumor
antigen-specific CD8+ T cells. Our data indicate that cblb target-
ing in T cells alone is not sufficient to counteract cancer-associated
immune suppression, but that reactivation of the engineered T
cells by a DC vaccine induces a profound anti-tumor immune
response in non-TCR-transgenic mice (74).
Cbl-b FUNCTION IN NK CELLS
Cbl proteins not only regulate adaptive immune cell functions but
are also critically involved in the regulation of innate lymphocyte
populations, such as NK cells (89). NK cells are among the first
cells to arrive at the inflamed tissue where they exert potent cyto-
toxic effector functions and modulate the local immune response
(96). In addition, NK cells are critically involved in immunosur-
veillance of cancer (97). The cytotoxic effects of NK cells and their
ability to secrete cytokines is regulated by a multitude of activat-
ing and inhibiting receptors, which are expressed in a variety of
combinations in the different NK cell subsets (98). Initial work
on the role of Cbl proteins in NK cells was restricted to c-Cbl,
with early reports demonstrating phosphorylation of c-Cbl after
activation of NK cells by various stimuli (99–101). It was shown
that this leads to interaction with adaptor molecules of several
signal transduction pathways (99, 102) but the functional conse-
quences remained unclear until the group of Long showed that
c-Cbl imposes a block, which can only be released by two strong
synergistic activating signals. Signals through activating NK cell
receptors lead to integration of c-Cbl into a macromolecular com-
plex consisting of the adaptor Crk, the scaffold protein p130CAS
and the guanine-nucleotide exchange factor C3G, which is criti-
cal for signaling in a wide variety of pathways. Inhibitory signals
through KIR receptors inhibit formation and result in disassembly
of this complex (103). Interestingly, there was no evidence that E3
ligase function of c-Cbl plays a role in this process. In follow up
publications, it was shown that two synergistic activating signals,
for example, through NKG2D and CD244 are needed to overcome
blockade by c-Cbl (104) and that this synergistic action is medi-
ated by a combined phosphorylation of separate tyrosine residues
of the adaptor protein SLP-76 (105). On the other hand, c-Cbl is
involved in a kind of negative feedback loop in the down regu-
lation of NKG2D after prolonged exposure to one of its ligands,
MICA (106).
Very recently, an elegant study involving genetic ablation of
cblb demonstrated a prominent role also of Cbl-b for activation
and effector functions of NK cells. Knockout of cblb resulted in
increased cytotoxicity as well as higher production of IFN-γ and
perforin (89). Site directed mutagenesis resulting in functional
inactivation of the catalytic domain further confirmed that the E3
ligase activity is necessary for this effect. Moreover, cblb-deficient
NK cells were able to prolong survival and reduce metastasis in
several tumor models. Members of the TAM family of cell surface
tyrosine kinase receptors (107) were identified as prime targets for
Cbl-b-mediated ubiquitination in NK cells (Figure 2). Apparently,
Cbl-b ubiquitinates all three TAM family members, Tyro-3, Axl,
and Mer, and controls TAM receptor internalization, which is nec-
essary for their functional activity. Small molecule inhibitors of
TAM receptor kinases increased NK cell cytotoxicity to the same
extent as seen in Cbl-b-deficient animals. Together, these data show
that Cbl-b is a key regulator of NK cell effector mechanisms and
that down modulating Cbl-b function or inhibiting its substrates
is a promising approach in cancer immunotherapy.
Cbl-b FUNCTION IN B CELLS
Production of autoantibodies is a prominent feature of cblb−/−
mice (4, 108) leading to the hypothesis that Cbl-b participates
in negative regulation of B cell activation pathways (Figure 2).
Moreover, B cell-specific ablation of both c-Cbl and Cbl-b in mice
displays only slight developmental changes of B cells such as an
increase in B1 cells and marginal zone B cells but causes aberrant
B cell receptor (BCR) signaling and impaired anergy in mature
B cells culminating in the development of a systemic lupus ery-
thematosus like disease (109). Many of the interaction partners
of Cbl-b documented for T cells such as PLCγ2, p85/PI3K, or the
nucleotide exchange factor Vav are also involved in the normal
signal cascade in B cells after activation of the BCR. Therefore, it is
likely that they are also targeted by Cbl-b in B cells. Indeed, early
work with a chicken B cell line documented direct association of
Cbl-b with PLCγ2 (110). However, in contrast to c-cbl (111), knock
down of cblb resulted in reduced PLCγ2 activation in chicken
B cells whereas overexpression of Cbl-b in a mouse B cell line
lead to increased Ca++ mobilization. Together with PLCγ2, Cbl-b
formed a complex with BTK and the BLNK and was indispensable
for sustained intracytoplasmic Ca++ concentrations, suggesting
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a positive regulation of BCR-mediated signaling by Cbl-b (110).
These findings from B cell lines is in strong contrast to work with
primary mature mouse B cells, where cblb-deficient cells display
enhanced proliferative responses upon stimulation via BCR or
CD40 (Figure 2) (4) and sustained phosphorylation of compo-
nents of the BCR signaling complex as well as prolonged Ca++
fluxes (112). The regulation of B cell activation is seemingly medi-
ated by an interaction of Cbl-b with the spleen tyrosine kinase
Syk leading to its ubiquitination and possibly degradation (112).
Syk is also targeted by c-Cbl (113). Another important signal-
ing pathway regulated by Cbl-b is the interaction between CD40L
on T cells and CD40 on B cells, which plays a central role in
homeostatic regulation of B cell function. Cblb-deficient B cells
display hyperproliferation and increased survival in response to
CD40 stimulation (108). In addition, T cell independent antibody
production is increased in cblb−/− mice. Elegant experiments,
where rag−/− mice were reconstituted with cblb-deficient B cells
and wt T cells, demonstrated that also T cell dependent anti-
body titers against the keyhole limpet hemocyanin (KLH) model
antigen are increased (108). Nevertheless, reconstitution with a
combination of cblb-deficient T and B cells further increased KLH-
specific humoral immune response. In the absence of Cbl-b, IκBα
and JNK were selectively hyperphosphorylated suggesting that of
the different signaling pathways downstream of CD40, NF-κB
seems to be specifically targeted by Cbl-b (108). TNF receptor-
associated factors (TRAF) are important adaptor molecules and
their recruitment to the cytoplasmic tail of CD40 is essential for
CD40-mediated signal transduction. It was demonstrated that
Cbl-b binds to TRAF-2, another E3 ligase leading to its ubiquiti-
nation thereby facilitating access of the negative regulator TRAF-3
(108), which results in NF-κB activation.
In human B cells, both c-Cbl and Cbl-b are constitutively asso-
ciated with CIN85 forming a complex with BLNK (114). This
interaction with CIN85 also promotes degradation of Syk. How-
ever, it was so far not investigated whether c-Cbl or Cbl-b is
responsible for this molecular effect.
B cells not only produce antibodies but are also involved in anti-
gen processing and presentation to T cells. Recently, it was shown
that Cbl-b but not c-Cbl is required for endocytic trafficking of the
BCR complex together with the captured antigen to the MHC II
containing late endosomes (115). Although BCR is ubiquitinated
following stimulation, this seems not to be mediated by Cbl-b as
Cbl-b constructs lacking E3 ligase activity were able to reconstitute
BCR sorting to late endosomes in cblb−/− cells. Rather the UBA
domain is required for endocytic trafficking, possibly acting as a
scaffold.
Taken together, there is evidence that both c-Cbl and Cbl-b
regulate the B cell activation process and thus fine-tune humoral
immune response. The relative contribution of the two Cbl pro-
teins in the various physiological and pathological settings still
awaits rigorous investigation.
Cbl-b FUNCTION IN DENDRITIC CELLS
Dendritic cells are leukocytes whose main function is to capture
and process antigens and to present them to cells of the adaptive
immune system in order to activate or tolerize them. Immature
DCs are characterized by high endocytotic activity and sense and
uptake pathogens through pattern recognition receptors (116).
Antigens are then presented to T cells in the tumor draining lym-
phnode. In the same time, DCs up-regulate co-receptors such as
CD80, CD86, and CD40, thereby enhancing their T cell stimu-
lation capacity. This results in the differentiation and activation
of antigen-specific T-lymphocytes, enabling them to exert their
specific effector functions (117).
The E3 ligase c-Cbl has been identified as a modulator of DC
activation (118). Toll-like receptor (TLR)-induced expression of
pro-inflammatory cytokines and chemokines, such as IL-1α, IL-
1β, IL-6, IL-12p70, and CXCL1/KC was enhanced in ccbl-deficient
DCs upon LPS exposure. Up-regulation of cytokines was accom-
panied by enhanced NF-κB transactivation. Loss of c-Cbl did not
only up-regulate expression of TLR-triggered pro-inflammatory
cytokines but also increased basal expression under steady-state
conditions. By overexpressing several mutants of c-Cbl in ccbl
knockout DCs before LPS stimulation, the authors proved that
the RING domain of c-Cbl is required for IL-12 inhibition. Fur-
thermore, in vivo proliferation of CD4+ and CD8+ T cells was
enhanced in mice vaccinated with OVA-pulsed DCs from ccbl
negative donors compared to the group treated with wt DCs.
Splenocytes from mice primed with ccbl-deficient DCs demon-
strated higher peptide specific cytotoxicity, higher numbers of
IFN-γ secreting CD4+ and CD8+ T cells, whereas IL-4 secre-
tion was unaltered. Thus, DC deficient for ccbl is more potent
inducers of TH1 polarization. To assess whether ccbl-deficiency
in DCs would increase their ability to reject tumors, immune
competent C57BL/6 wt mice were subcutaneously injected with
OVA-expressing EG.7 lymphoma cells and vaccinated with either
wt or ccbl-deficient bone marrow derived DCs (BMDCs). Tumor
growth in mice treated with ccbl-deficient DCs was significantly
delayed compared to the control groups suggesting that inhibition
of c-Cbl could probably improve DC based vaccines (118).
Besides c-Cbl, DCs also highly express Cbl-b (119), which
might be involved in a negative feed back loop regulating TLR
signaling (120). Along this line, it was demonstrated that low-
avidity outside-in signaling through CD11b negatively regulates
TLR signaling in macrophages through increased Cbl-b-mediated
degradation of MyD88 and TRIF. In addition, activation of Akt
kinase after binding of either RANK or CD40 to their cognate lig-
ands is dependant on Cbl-b, whereas in B cells c-Cbl is involved
(121).
Since cblb-deficient mice are largely protected from tumor
formation (72, 73) and adoptive transfer of cblb negative or tran-
siently silenced CD8+ T cells in combination with DC vaccination
delays tumor growth in several mouse models (74, 122) it was
interesting to know whether loss of Cbl-b in DCs also contributes
to tumor resistance of cblb knockout animals (119). We confirmed
high expression of Cbl-b in murine BMDCs and showed that
cblb-deficiency did not alter BMDC differentiation in vitro. While
expression of several functionally important surface proteins on
immature and LPS-stimulated DCs was unchanged between wt
and cblb negative DCs, we found increased DEC-205 expression
on cblb knockout cells (119). Since DEC-205 expression is associ-
ated with Treg induction (123), this could at least in part explain
the increased frequency of tumor-infiltrating Treg in cbl-b nega-
tive mice (72). When comparing secretion of pro-inflammatory
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cytokines and chemokines in wt versus cblb-deficient BMDCs
using different stimulation regimens, we found that LPS-induced
TLR4 stimulation resulted in significantly increased TNF-α, IL-6,
and MIP-1α secretion in cblb knockout DC. Similarly, TNF-α,
together with IL-1α and MCP-1, was increased upon stimu-
lation by the TLR-9 agonist CpG in cblb negative DCs com-
pared to wt DCs. Both, TLR4 and TLR9 stimulation, induce a
MyD88-dependent signaling pathway leading to production of
pro-inflammatory cytokines and chemokines. This is in accor-
dance with the role of Cbl-b in MyD88 degradation and sub-
sequent suppression of MyD88 inflammatory responses (120).
Stimulation with TLR3 agonists did not result in different cytokine
profiles of wt and cblb-deficient DCs consistent with a predom-
inantly MyD88-independent signaling by this TLR (124). While
cblb-deficient DCs induce stronger allogeneic T cell responses,
antigen-specific T cell proliferation was unaltered in vitro and
in vivo (119). Increased cytokine production of cblb negative DCs
seems to be insufficient to influence peptide-induced proliferation
of OT-I tg CD8+ and OT-II tg CD4+ T cells, maybe due to the fact
that OT-I and OT-II T cells proliferate even upon stimulation with
very low antigen concentrations. Also, cross-presentation capac-
ity of BMDCs was not affected by loss of Cbl-b. According to our
in vitro findings, the anti-tumor responses in mice vaccinated with
OVA-peptide-loaded DC were not different between the various
genotypes (119). Therefore, and in contrast to c-Cbl targeting,
silencing of Cbl-b in DC seems to be less promising for improving
the T cell priming capacity of DC vaccines.
Cbl-b FUNCTION IN MYELOID/MONOCYTIC CELLS
In comparison to other cell types, less is known on the role of
Cbl-b in cells of myeloid origin. In the initial description of Cbl-b,
it was already shown that it is up-regulated in human myeloid cell
lines upon differentiation (19), however, only recently evidence
is emerging how Cbl-b controls several aspects of myeloid cell
function. It is involved in negative feed back loops of TLR signal-
ing (120) and regulates macrophage activation by fatty acids (125).
Cblb-deficient mice display enhanced infiltration and activation of
macrophages, resulting in peripheral insulin resistance (126) and
the aggravated lung inflammation seen after LPS induced sepsis
in cblb-knockout mice is at least in part mediated by increased
activation of macrophages (127). In this context, it is also interest-
ing to note that specific mutations of Cbl proteins, mainly c-Cbl
and to a lesser extent also Cbl-b, have been associated with cer-
tain myeloproliferative disorders (128, 129), already pointing out
to an important role of these proteins for myeloid cell biology. In
addition, c-Cbl is frequently mutated in advanced mastocytosis or
mast cell leukemia (130). The mutations found not only in ccbl
but also in cblb are located mainly in the RING finger (RF) and
linker domains, clustering in and around the binding pocket for
E2 interactions, suggesting that loss of E3 ligase activity is impor-
tant for the oncogenic process (131). These clinical findings are
endorsed by studies using mice with hematopoietic cells deficient
of both ccbl and cblb, which display rapidly fatal myeloproliferative
disease (132).
However, Cbl proteins are also relevant in the non-cancer set-
ting in myeloid cells. As an example, challenging mice with LPS
lead to severe acute lung inflammation, which is more pronounced
in cblb knockout animals (127). In this TLR4-dependent model of
sepsis stimulation with LPS increased activation of neutrophils
as evidenced by augmented CD11b expression and CD62L shed-
ding. In addition, production of TNF-α and MIP-1α after LPS
stimulation was higher in cblb-deficient animals, whereas other
cytokines such as RANTES and IL-6 remained unchanged but
showed Cbl-b dependent regulation when polymicrobial sepsis
was induced after cecal ligation and puncture (127), or after
cardiotoxin-induced muscle damage (133). Genetic ablation of
cblb, however, had no obvious effect on cytokine production after
stimulation with TLR3 agonists (127), which is in line with our
observation using BMDC (119). It was also demonstrated that
Cbl-b controls TLR4 signaling (Figure 2) via rapid down regu-
lation of TLR4 and by regulating the association between TLR4
and the adaptor molecule MyD88. Although Cbl-b seems to be
required for TLR4 ubiquitination under resting conditions, down
regulation of TLR4 after activation was not due to Cbl-b-mediated
ubiquitination and degradation (127). Later, it was shown that
Cbl-b regulates LPS-induced TLR4 signaling by ubiquitination of
the adaptor molecules MyD88 and TRIF (120). Stimulation of
TLR4 with saturated fatty acids, however, induced ubiquitination
and degradation of TLR4 in a Cbl-b dependant manner without
ubiquitination of MyD88 or TRIF (125). Thus, Cbl-b is involved in
the control of TLR4-mediated activation of myeloid cells through
different mechanisms depending on the actual stimulus.
Toll-like receptor-triggered responses are regulated through
several negative feedback loops. Signaling through the integrin
CD11b activates Syk leading to degradation of the TLR adap-
tor molecules MyD88 and TRIF by Cbl-b. For this process, the
E3 ligase activity is required (120). In contrast, another integrin-
mediated pathway to dampen TLR induced activation is inde-
pendent of this Cbl-b/MyD88 regulatory axis (134). Adhesion
to endothelial cells is an important step in the recruitment of
mononuclear phagocytes to inflamed tissue. Of the various adhe-
sion molecule interactions involved, association of LFA-1 with
ICAM-1 but not VLA-4-mediated adhesion is regulated by Cbl-b.
Cblb-deficient cells showed increased association of the LFA-1 β
chain with 14-3-3β, one of the cytoplasmic factors transmitting
inside-out activating stimuli (135).
Using bone marrow-derived mast cells from mice and the rat
basophilic leukemia cell line RBL-2H3 quite some information has
been gathered on the role of Cbl-b in mast cells. While both c-Cbl
and Cbl-b are expressed in rodent mast cells and become tyro-
sine phosphorylated upon FcεRI engagement (136) for human
cells only data on c-cbl exist. In the rodent models, Cbl-b but
not c-Cbl has been associated with reduced phosphorylation of
various proteins involved in the signaling cascade such as Syk
(136, 137), resulting in a negative regulation of FcRεI-induced
degranulation (136) and cytokine production (138). Mice geneti-
cally engineered to express Cbl-b with a dysfunctional RF domain
revealed increased phosphorylation of tyrosine kinases Syk and
Lyn and downstream substrates such as LAT (linker for activation
of T cells) as well as PLCγ1 (91), similar to that found in mast cells
of Cbl-b-deficient mice indicating that the E3 ligase activity is nec-
essary. However, downstream effects seemed to be differentially
affected. Phosphorylation of IKKα/β and cytokine production
were much stronger in cells where the complete Cbl-b protein
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was missing compared to cells with a Cbl-b protein mutated in
the RF. This shows that the regulatory function of Cbl-b for IgE-
induced inflammatory cytokine production is largely independent
of the RF domain (91).
Cbl-b is also involved in the regulation of osteoclast activ-
ity as cblb-deficient mice display osteopenia (139). It was later
shown that bone resorption is predominantly regulated by Cbl-b,
whereas osteoclast survival is dependent on interaction between c-
Cbl and PI3K (140). Thus, Cbl-b may also serve as potential target
to modify bone metabolism in diseases such as osteoporosis.
Cbl-b IN AUTOIMMUNITY
As genetic ablation of cblb is associated with spontaneous develop-
ment of autoimmunity and increased susceptibility to experimen-
tal induction of autoimmune diseases (4, 5) it is not surprising that
several groups later found links between genetic cblb variants and
susceptibility to autoimmunity in an animal model for diabetes
(141) as well as in various human autoimmune diseases such as
type 1 diabetes (142), lupus erythematodes (143), asthma (144),
and multiple sclerosis (145–147). Some of the single nucleotide
polymorphisms have been found in the promoter region, possibly
influencing transcriptional regulation. Indeed, reduced expression
of Cbl-b in PBMC, or more specifically in CD4+ T cells, was a com-
mon finding in several autoimmune diseases (143, 148–150) and
CBLB mRNA levels in T cells were inversely correlated with relapse
rates in multiple sclerosis patients (151). Consistent with reduced
Cbl-b levels, several studies also demonstrated increased prolifera-
tion of T cells from autoimmune patients especially under anergic
conditions (149, 150) and reduced susceptibility to inhibition by
Treg (148). A recent study demonstrated that the transcription
factor C/EBPβ displayed stronger binding to a disease associated
variant and that the negative effect of IFN-β stimulation on T cell
proliferation was compromised in CBLB risk allele carriers (150).
The functional consequences of other variants, especially in the
coding region of CBLB still await elucidation.
IMPROVING CANCER IMMUNOTHERAPY BY TARGETING
Cbl-b IN CLINICAL SETTINGS
Translation of Cbl-b targeting to clinically applicable concepts
requires transient and reversible inhibition of Cbl-b activity.
Therefore, we established a synthetic siRNA transfection protocol
and demonstrated that transient siRNA-mediated cblb silencing
results in hyperresponsiveness, decreased TGF-β sensitivity, and
increased IFN-γ production (122). Repeated adoptive cell therapy
of cblb silenced T cells in combination with the DC vaccine resulted
in delayed tumor outgrowth and prolonged survival rates without
overt signs of autoimmunity. In agreement with the phenotype of
cblb-deficient murine CD8+ T cells, siRNA-mediated knockdown
of CBLB in naive human CD8+ T cells similarly shows markedly
enhanced IFN-γ production, even in the absence of CD28 co-
stimulation. CBLB mRNA was almost undetectable for 1 week
suggesting that nucleofected T cells should stay hyperreactive for
several days within the patient upon adoptive transfer (122, 152).
We here envision using CBLB silenced autologous cells as com-
bination partner for other immune activating therapies, such as
checkpoint monoclonal antibodies, DNA-based vaccines, and DC
vaccination (153, 154).
Adoptive cell therapies have achieved promising results in
clinical trials. Ex vivo expanded tumor-infiltrating lympho-
cytes (TILs) have induced regression in patients with metastatic
melanoma (155, 156) and virus-specific T cells are used in virus-
associated hematologic malignancies (157). Efficacy of adoptive
immunotherapy can be increased by ex vivo gene transfer in order
to bypass the need of the ex vivo expansion and accumulation
of tumor-specific T cells prior the ACT (158–160). Nevertheless,
although tumor-specific immune responses are often induced, the
therapeutic efficacy of these approaches is limited because of insuf-
ficient in vivo activation, expansion, and survival of transferred
effector immune cells (159). In addition, the restricted knowledge
of tumor antigens that are capable to induce potent anti-tumor
immune responses limits the applicability of ACT therapies so far.
Besides the unsatisfactory clinical benefit, another disadvantage
of common ACT approaches is that they generally require time-
and cost-consuming protocols to generate enough tumor-reactive
CD8+ T cells. Moreover, the use of lentiviral vectors to generate
TCR-transgenic T cells harbors the risk of insertional mutagen-
esis, potentially causing leukemogenesis (161). Therefore, using
hyperreactive polyclonal non-TCR-transgenic T cells instead of
tumor-specific cells for ACT in combination with a second stim-
ulus as, for example, DC vaccination would simplify the standard
operating procedure. Strategies rendering adoptively transferred
effector cells resistant to inhibitory cues from the microenviron-
ment are highly attractive for improvement of the efficacy of
cancer immunotherapy. Our results obtained in preclinical mouse
models suggest that transient siRNA-mediated CBLB targeting in
polyclonal CD8+ T cells may improve adoptive T cell therapy in
the clinic (74, 122, 152). Moreover, decreasing Cbl-b expression
of NKT cells stimulated by α-galactosylceramide for ACT (162)
may render them resistant to anergy (163) thus improving ACT
(164). Alternatively, other stimulating ligands, which do not up-
regulate Cbl-b in NKT cells may be useful in the clinical setting
(163). As recently shown, also NK cell-based immunotherapies
are amenable to improvement by modulation of Cbl-b. Adoptive
transfer of cbl-b deficient NK cells significantly reduced tumor
burden in a melanoma mouse model (89). Similar effects can also
be achieved by inhibiting the most prominent targets of Cbl-b
ubiquitination in NK cells, the TAM receptor kinases with small
molecule compounds.
FINAL COMMENTS
Although relatively little information is available regarding the
mechanisms of Cbl-b in human cells ample evidence indicates
that Cbl-b exerts important regulatory functions in diverse cells of
hematopoietic origin, resulting in a balanced immune response.
Depending on the clinical situation, either inhibiting or strength-
ening Cbl-b functions might be desirable. In the autoimmune
setting, inhibition of degradation of Cbl-b interaction partners by
proteasome inhibitors could constitute a rationale approach (1).
Vice versa, anti-cancer immunity could be enhanced by direct or
indirect inhibition of Cbl-b function. Small molecule inhibitors
specific for Cbl-b have not yet been developed. However, inhibi-
tion of molecular substrates of Cbl-b ubiquitination such as TAM
receptors that successfully increased NK cell-mediated cytotoxi-
city and reduced metastatic spread are promising candidates to
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be tested in clinical trials (89). Also, the recent promising results
of clinical studies with immune checkpoint antibodies may be
based on Cbl-b. Another way to harness this regulatory path-
way for reinforcing tumor-specific cells is to down modulate
Cbl-b by molecular means (e.g., by siRNA) for adoptive cel-
lular immunotherapy. The feasibility of such an approach will
soon be investigated in a phase I clinical study (NCT02166255).
In summary, targeting the immunological gate keeper Cbl-b
opens new avenues to treat human diseases, such as cancer and
autoimmunity.
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